UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000036050
Receipt number R000041006
Scientific Title The analysis of endometrial microbiota using the test named EMMA/ALICE to improve reproductive outcomes in infertile patients
Date of disclosure of the study information 2019/03/01
Last modified on 2023/01/06 09:56:18

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The analysis of endometrial microbiota using the test named EMMA/ALICE to improve reproductive outcomes in infertile patients

Acronym

EMMA/ALICE for RIF or RPL in Japan 2019

Scientific Title

The analysis of endometrial microbiota using the test named EMMA/ALICE to improve reproductive outcomes in infertile patients

Scientific Title:Acronym

EMMA/ALICE for RIF or RPL in Japan 2019

Region

Japan


Condition

Condition

Chronic endometritis

Classification by specialty

Obstetrics and Gynecology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the uterine microbiota and bacteria cause of chronic endometritis

Basic objectives2

Others

Basic objectives -Others

To evaluate the effect of the antibiotic therapy for chronic endometritis (CE) on IVF outcome

Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Phase IV


Assessment

Primary outcomes

The clinical pregnancy rate of the patients whose results are abnormal in EMMA/ALICE and after that who have treated with probiotics therapy

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Endometrial tissue will be obtained by aspiration from these patients on the day of endometrial biopsy in day 15-25 of menstrual cycle. Samples of these patients will ill be used for the non-invasive diagnosis of the endometrial factor and microbiome by NGS.

Interventions/Control_2

Those patients dominated by bacteria of the genus Lactobacillus will continue their ART according to the standard protocol of the clinic. Those patients without dominated by bacteria of the genus Lactobacillus will follow the recommendation therapy, after a second endometrium sample will be obtained, in which the collection of endometrium sample will be repeated as previously described. Finally, the endometrial factor will be correlated with that on the endometrial tissue and the microbiome according to the reproductive outcomes of these patients following the first embryo transfer performed after the sample collection

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

46 years-old >

Gender

Female

Key inclusion criteria

1, The patients who has IVF-ET therapy
2, The duration of infertility over 3 years
3,Infertile women with history of recurrent implantation failure, defined as three or more failed ETs, undergoing one or more IVF cycle(s).t
4, Infertile women with history of recurrent pregnancy loss, defined as two ore more
5, Infertile women with history of recurrent chemical pregnancy, defined as two ore more
6,The patients suspected CE by hysteroscope
7,The patients who detected CD138 positive plasma cells in historical tissues
8, The patients who had bacterial vaginosis
9,BMI: 18.5 - 30 kg / m2 (both inclusive)
10,HIV, HBV, HCV, RPR negative

Key exclusion criteria

1, The patients who has endometrial polyp, submucosal myopia, Asherman syndrome, scar of C/S in uterus.
2,Any social, medical, or psychiatric condition
3, The couple or their parents who has chromosomal aberration or carrier of translocation
4, The patients with untreated hydrosalpinx
5, Known allergy to any component of antibiotic therapy
6,,Vaginal or systemic antibiotic therapy within 3 months

Target sample size

300


Research contact person

Name of lead principal investigator

1st name Hirobumi
Middle name
Last name Kamiya

Organization

Kamiya Ladies Clinic

Division name

Reproductive Center

Zip code

0600003

Address

Nittsu-Sapporo Bldg 2F 2-1 Nishi 2-chome Kita 3-Jo Chuo-ku, Sapporo 060-0003 Japan

TEL

011-231-2722

Email

kamiya@fine.ocn.ne.jp


Public contact

Name of contact person

1st name Nanako
Middle name
Last name Iwami

Organization

Kamiya Ladies Clinic

Division name

Reproductive Center

Zip code

060003

Address

Nittsu-Sapporo Bldg 2F 2-1 Nishi 2-chome Kita 3-Jo Chuo-ku, Sapporo 060-0003 Japan

TEL

011-231-2722

Homepage URL


Email

nanakoiwami@gmail.com


Sponsor or person

Institute

Kamiya Ladies Clinic

Institute

Department

Personal name



Funding Source

Organization

Self funding

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kamiya Ladies Clinic

Address

Nittsu-Sapporo Bldg 2F 2-1 Nishi 2-chome Kita 3-Jo Chuo-ku, Sapporo 060-0003

Tel

011-231-2722

Email

kamiya@fine.ocn.ne.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 03 Month 01 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications


Number of participants that the trial has enrolled

200

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2019 Year 02 Month 04 Day

Date of IRB

2019 Year 02 Month 23 Day

Anticipated trial start date

2019 Year 02 Month 24 Day

Last follow-up date

2022 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded

2022 Year 09 Month 01 Day


Other

Other related information



Management information

Registered date

2019 Year 02 Month 28 Day

Last modified on

2023 Year 01 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041006


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name
2022/10/19 Data sets updates2.xlsx